Retinal Break
Retina360: Advances in the Treatment of Geographic Atrophy and Retinal Vein Occlusion
This activity is supported by independent medical education grants from Regeneron Pharmaceuticals, Inc.; Astellas; Alimera Sciences, Inc.; Ocular Therapeutix, Inc.; Outlook Therapeutics; and REGENXBIO Inc.
Retina360: Advances in the Management of Neovascular AMD and Sustained Drug Delivery for Retinal Diseases
This activity is supported by independent medical education grants from Regeneron Pharmaceuticals, Inc.; Astellas; Alimera Sciences, Inc.; Ocular Therapeutix, Inc.; Outlook Therapeutics; and REGENXBIO Inc.
In Case You Missed: The Promise of Tyrosine Kinase Inhibitors in the Treatment of Retinal Disease
This activity is supported by an educational grant from Ocular Therapeutix, Inc.
Retina expert shares vitrectomy pearls for cataract surgeons
VIDEO: Personalize treatment, referral for each patient with retinal break
Jessica Steen, OD, FAAO, says that her lecture at this year’s SECO meeting on retinal breaks covered personalized treatment paths for patients, including those who may go on to develop retinal detachment.
Follow-up important in patients with acute posterior vitreous detachment
PHILADELPHIA — Delayed retinal breaks and retinal detachments occur more often after acute posterior vitreous detachment in patients with underlying risk factors, according to a study presented at Wills Eye Conference.